Publications by authors named "Hiroaki Amano"
Objective: To determine the long-term survival of patients receiving home hemodialysis (HHD) through self-punctured arteriovenous access.
Methods: We conducted an observational study of all patients receiving HHD at our facility between 2001 and 2020. The primary outcome was treatment survival, and it was defined as the duration from HHD initiation to the first event of death or technique failure.
Background/aim: Membranous nephropathy (MN) is a nephrotic syndrome with both idiopathic and secondary etiologies. The mechanism of cancer-associated MN is presumed to involve the immunological production of antibodies against a tumor antigen, although little is known about the detailed mechanism. Lung cancer is a major neoplasm associated with cancer-associated MN.
View Article and Find Full Text PDFArticle Synopsis
- - A 75-year-old woman with colon cancer developed massive proteinuria after treatment with FOLFIRI and bevacizumab, leading to the discontinuation of only bevacizumab, which initially improved her condition.
- - More than six months later, she experienced a recurrence of proteinuria and declining kidney function, with a biopsy revealing damage due to chronic endothelial cell issues thought to be related to bevacizumab and other chemotherapy drugs.
- - Despite attempts to manage her condition through diet and antihypertensive therapy, the patient's ability to continue chemotherapy suffered, indicating that careful monitoring and management of related health issues are essential in cancer treatments to prevent renal complications.
Article Synopsis
- CCN2/connective tissue growth factor (CTGF) is being researched as a potential treatment for chronic kidney disease, specifically focusing on its module-4 encoded by exon 5.
- Exon 5 knockout mice were created to study the impact of CCN2 module-4 on renal fibrosis using various models, such as unilateral ureteral obstruction and nephrectomy.
- The study found that these knockout mice exhibited significantly reduced interstitial fibrosis and lower levels of phosphorylated focal adhesion kinase (FAK), highlighting the CCN2 module-4-FAK pathway as a promising therapeutic target to combat renal fibrosis.
Renal interstitial fibrosis is the final common pathway in the process of all kidney diseases, and it results in chronic kidney disease. CCN2 is an important factor in the pathogenesis of renal interstitial fibrosis, and analysis of its function can lead to treatments for chronic kidney disease. Since CCN2 knockout mice are developmentally lethal, generation of conditional knockout mice is essential for in vivo analysis.
View Article and Find Full Text PDFArticle Synopsis
- Magnetic resonance imaging (MRI) is becoming vital for assessing chronic kidney disease (CKD), capable of evaluating conditions and predicting disease progression.
- * Research compared different MRI sequences with estimated glomerular filtration rates (eGFR) to see how well they provided insights into kidney function.
- * The study found T2* values from BOLD MRI to be particularly useful for predicting rapid kidney decline, indicating a need for more investigation into this method for CKD assessment.
In the Original publication, Under the table 1, the number of participants in the April has been incorrectly published as 1373. The corrected table is given below.
View Article and Find Full Text PDFHere we evaluated the efficacy of depleting cellular communication network factor 2 (CCN2) produced by renal tubular epithelial cells in preventing the progression of severe acute kidney injury (AKI) to chronic kidney disease (CKD). We used conditional Ccn2 knockout mice in which expression of Ccn2 was controlled by γ-glutamyl transpeptidase promoter-regulated Cre recombinase. AKI was induced by ischemia-reperfusion injury.
View Article and Find Full Text PDFBackground: In April 2015, five types of phosphate binders (PBs) were available by prescription in Japan, namely calcium carbonate, sevelamer hydrochloride, lanthanum carbonate, bixalomer, and ferric citrate hydrate (FeC). FeC reduces serum phosphorus levels and increases the body's iron stores. However, it is unclear whether FeC lowers serum phosphorus relative to other agents in a regional practical setting.
View Article and Find Full Text PDF